Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:28 2024-06-10 am EDT 5-day change 1st Jan Change
323.3 GBX -2.12% Intraday chart for Haleon plc -0.55% +0.51%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Haleon: share price rises, Berenberg initiates buy decision CF
Transcript : Haleon plc Presents at 21st Annual dbAccess Global Consumer Conference 2024, Jun-05-2024 04:30 PM
Berenberg Initiates Haleon Coverage at Buy MT
HALEON : Berenberg initiates buy coverage CF
Berenberg raises Taylor Wimpey to 'buy' AN
Delaware judge lets more than 70,000 Zantac lawsuits go forward RE
Suave Brands Company LLC acquired ChapStick Brand of Haleon plc. CI
Bernstein becomes more optimistic for consumer goods - Henkel upgraded DP
UK's FTSE 100 Closes Lower Amid Inflation Focus MT
GSK Sells Remaining Stake in Haleon for $1.58 Billion MT
FTSE 100 slides; Eurozone inflation steady AN
London stocks dip as global rates outlook weighs RE
GSK sells remaining Haleon stake for GBP1.25 billion AN
FTSE 100 lacklustre as Wall Street rally ends AN
London stocks lacklustre but set for weekly gains RE
Land Securities ups dividend; GSK sells Haleon stake AN
GSK Divests Remaining Haleon Stake in GBP1.25 Billion Deal MT
GSK Sells Last Haleon Shares for $1.58 Billion DJ
GSK raises $1.5 bln from sale of remaining Haleon stake RE
GSK Raises About 1.25 Bln Stg Via Haleon Stake Sale RE
GSK to Sell Remaining Haleon Stake MT
An unknown buyer completed the acquisition of 4.2% stake in Haleon plc from GSK plc for £1.2 billion. CI
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update DJ
GSK intends to sell its remaining stake in Haleon RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion DJ
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.303 GBP
Average target price
3.646 GBP
Spread / Average Target
+10.40%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon : Healthy organic sales performance; guidance re-affirmed